| Literature DB >> 28413565 |
Marcel Hulst1,2, Alfons Jansman3, Ilonka Wijers1, Arjan Hoekman1, Stéphanie Vastenhouw2, Marinus van Krimpen3, Mari Smits1,2, Dirkjan Schokker1.
Abstract
BACKGROUND: Gene expression profiles of intestinal mucosa of chickens and pigs fed over long-term periods (days/weeks) with a diet rich in rye and a diet supplemented with zinc, respectively, or of chickens after a one-day amoxicillin treatment of chickens, were recorded recently. Such dietary interventions are frequently used to modulate animal performance or therapeutically for monogastric livestock. In this study, changes in gene expression induced by these three interventions in cultured "Intestinal Porcine Epithelial Cells" (IPEC-J2) recorded after a short-term period of 2 and 6 hours, were compared to the in vivo gene expression profiles in order to evaluate the capability of this in vitro bioassay in predicting in vivo responses.Entities:
Keywords: Amoxicillin; Broilers; Gene expression; Intestinal mucosa; Pigs; Rye; Zinc
Year: 2017 PMID: 28413565 PMCID: PMC5390468 DOI: 10.1186/s12263-017-0559-1
Source DB: PubMed Journal: Genes Nutr ISSN: 1555-8932 Impact factor: 5.523
Number of DEGs in all in vitro and in vivo datasets and number of overlapping genes and pathways between in vivo and in vitro datasets
| Comparison of treatmentsa | Species (age)b | Vitro concentration or dilution-factor diet (Rye) | Vivo concentration or dilution-factor diet (Rye) | Vivod day | Vivoe | Vitroe 2h/6h | Genes overlap 2h/6h | Pathways overlap 2h/6h |
|---|---|---|---|---|---|---|---|---|
| ZnO vs.Controla | pig (weaned) | 0.03125% w/v | 0.25% w/w | 23 | 101_36c | 174/720 | 4_1c/3_3c | 7_1c/2_0c |
| 35 | 11_11c | 0_1c/2_1c | 2_3c/2_4c | |||||
| Amoxicillin vs.Controla | Broiler (1d) | 0.5% w/v | 0.0067% w/v | 5 | 51 | 87/705 | 0/2 | 1/1 |
| 14 | 36 | 0/1 | 2/2 | |||||
| rye 10% vs. 0%a | Broiler (1d) | 3 | 1 | 21 | 238 | 568/21 | 9/1 | 1/1 |
| 28 | 219 | 8/0 | 3/3 | |||||
| rye 5% vs. 0%a | Broiler (1d) | 3 | 1 | 21 | 318 | 204/26 | 9/1 | 4/2 |
| 28 | 34 | 1/0 | 0/0 | |||||
| rye 10% vs.5% | Broiler (1d) | 3 | 1 | 21 | 47 | 455/17 | 0/0 | 1/0 |
| 28 | 192 | 6/0 | 4/0 |
aFor comparisons with IPEC-J2 cells, the ‘control’ (ZnO and amoxicillin) or ‘0%’ (rye) is a culture medium without additive or rye diet (except for the 10% rye vs. 5% rye comparison). For the ZnO in vivo experiment, the ‘contol’ is a regular diet with a normal level of Zn (60–100 mg/kg)
bAge of broilers at the start of the rye and amoxicillin interventions and age of piglets (weaned) at the start of the animal experiment. Piglets were fed with a diet with a higher dose of zinc oxide (2500 mg/kg) from days 14 to 23 post-weaning
cNumber of genes in the jejunum and number of genes in the ileum
dNumber of days of sampling of intestinal tissue
eNumber of DEGs with a p value <0.05 and absolute fold change of >2.0 or <0.5 in vitro and in vivo
Overlapping in vivo and in vitro DEGs and selected IPEC-J2 effector genes from ZnO, rye and amoxicillin datasets
| Gene symbol | Full name | Day in vivo/hours in vitro IPEC-J2 | Function/part of process |
|---|---|---|---|
| ZnO overlapping genes | |||
| ZFP36L2 | ZFP36 ring finger protein-like 2 | 23 days/2 h | Promotion mRNAs deadenylation and degradation |
| MT1A | Metallothionein 1A | 23 and 35 days-ileum-23 days-jej/2 and 6 h | Divalent metal ion transporter and scavenger of oxygen radicals |
| ZnO; putative IPEC-J2 effector genes | Related or overlapping in vivo pathway | ||
| HBEGF | HBEGF (heparin-binding EGF-like growth factor) | PAK pathway | Mitogenic for fibroblasts multiple organ systems |
| NRG1 | NRG1 (neuregulin 1) | PAK pathway | Growth and development of multiple organ systems |
| BMP2 | BMP2 (bone morphogenetic protein 2) | PAK pathway | Member TGF-beta superfamily/induces bone and cartilage formation |
| NGF | Nerve growth factor | PAK pathway | Nerve growth-stimulating activity |
| MT1A | MT1A (metallothionein 1A) | Mineral absorption | Divalent metal ion transporter and scavenger of oxygen radicals |
| HMOX1 | Heme oxygenase 1 | Mineral absorption | Enzyme heme catabolism/response to hypoxya/Fe2+ transport/regulation of vascular tone |
| SERPINE1 | SERPINE1 (serpin family E member 1) | Cell adhesion_ECM remodelling | Serine protease inhibitor/inhibitor of fibrinolysis |
| IL6 | Interleukin 6 | Influenza A/PAK pathway | Cytokine that induces inflammation and maturation of B cells |
| IFNL1 | Interferon λ1 | Influenza A/PAK pathway | Antiviral host defence in the epithelial tissues |
| IL1A | Interleukin 1A | Influenza A/PAK pathway | Pleiotropic cytokine/role in various immune responses and inflammation/antiviral response |
| IL8 | (Interleukin 8) | Influenza A/PAK pathway | Chemotactic factor attracting neutrophils, basophils, and T cells |
| IL21 | (Interleukin 21) | None | Cytokine promoting switch between innate and adaptive immunity |
| Rye overlapping genes | |||
| HOOK3 | Hook microtubule-tethering protein 3 | 10% 21 days, 10 vs. 5% 28 days, 10% 28 days/2 h | Component FTS/Hook/FHIP complex/vesicle trafficking |
| PTEN | Phosphatase and tensin Homolog | 10% 21 days, 10 vs. 5% 28 days, 10% 28 days/2 h | Protein tyrosine Phosphatases/negatively regulating AKT-PKB signalling |
| ZFYVE16 | Zinc finger, FYVE domain-containing 16 | 10% 21 days, 10 vs. 5% 28d/2 h | Recruits TGF transcriptional modulators/membrane trafficking endosomes |
| CCK | Cholecystokinin | 10% 21 days, 10 vs. 5% 28d/2 h | Peptide hormone induces release of pancreatic enzymes |
| NOG | Noggin | 5% 21 days/2 h | Inactivates members of TGF-beta family signalling proteins (e.g BMPs) |
| MUC(17) | Mucin 17, cell surface-associated | 5%-21d, 10% vs. 5% 21d/6 h | Membrane-bound mucin that provides protection to gut epithelial cells |
| Rye; putative IPEC-J2 effector genes | Related or overlapping in vivo pathway | ||
| TNF | Tumour necrosis factor | TGF-beta signalling | Multifunctional proinflammatory cytokine |
| FST | Follistatin (activin-binding protein) | TGF-beta signalling | Inhibits follicle-stimulating hormone release/antagonist of INHBA |
| RICTOR | RPTOR independent companion of MTOR complex 2 | mTOR signalling | Subunit of mTORC2/regulates cell growth and survival in response to hormones |
| DDIT4 | DNA damage-inducible transcript 4 | mTOR signalling | Regulation cell growth and survival/inhibition activity mTORC1 in response of hypoxia |
| MUC(4) | Mucin 4, cell surface-associated |
| Sialomucin/intestinal epithelial cell differentiation/EGF cell signalling |
| MUC(13) | Mucin 13, cell surface Associated |
| Epithelial and hemopoietic transmembrane mucin/EGF cell signalling |
| B3GALT1 | Beta-1,3-galactosyltransferase 1 |
| Transfers galactose from UDP galactose to a terminal beta- |
| Amoxicillin-overlapping genes | |||
| OSER1 | Oxidative stress responsive serine-rich 1 | 5/2 h | Cellular response to hydrogen peroxide/UBC binding |
| ZBTB17 | Zinc finger and BTB domain-containing 17 | 5/6 h | c-MYC transcriptional repression (regulation of cell cyle) |
| MID1IP1 | MID1-interacting protein 1 | 5/6 h | Negative regulation of microtubule (de)polymerisation/UBC binding |
| STMN1 | Stathmin 1a | 5 and 14/ | Prevents assembly and promotes disassembly of microtubules/UBC binding |
| EREG | Epiregulina | 5 and 14/ | Member of the epidermal growth factor family/UBC binding |
| CLTA | Clathrin, light chain Aa | 5 and 14/ | Coated pits and vesicles and receptor-mediated endocytosis/UBC binding |
| ARPC1A | Actin-related protein 2/3 complex, subunit 1Aa | 5 and 14/ | Actin polymerisation-forming of filopodia or stress fibres/UBC binding |
| Amoxicillin; putative IPEC-J2 effector genes | Related or overlapping in vivo pathway | ||
| HMOX1 | Heme oxygenase 1 | HIF1A pathway | Essential enzyme heme catabolism/response to hypoxia/regulation of vascular tone |
| HK2 | Hexokinase 2 | HIF1A pathway | Phosphorylate glucose to produce glucose-6-phosphate |
| PDK1 | Pyruvate dehydrogenase kinase 1 | HIF1A pathway | Regulation of glucose and fatty acid metabolism/upregulated in response to hypoxia |
| EDN1 | Endothelin 1 | HIF1A pathway | Potent vasoconstrictor |
| NPPA | Natriuretic peptide A | HIF1A pathway | Regulation blood pressure and body fluid homeostasis |
| MID1 | Midline 1 RING finger protein | Microtubule | E3 ubiquitin ligase/microtubule (de)polymerisation/UBC binding |
aIn addition to overlapping genes for amoxicillin information of DEGs in the in vivo dataset related to overlapping pathways and regulated at both time points (5 and 14 days) is provided
Pathways/processes and GO-terms overlapping between in vitro and in vivo datasets
| System/additive | Time | Pathway or Go-term | Scorea | No. of total genesb | No. of DEGsd | Response genese |
|---|---|---|---|---|---|---|
| Overlap Zno | ||||||
| Ileum/ZnO | 23 days | Mineral absorption | 15.1 | 51 | 4 | SLC39A4, MT1F, HEPH, |
| IPEC-J2/ZnO | 2 h | Mineral absorption | 20.4 | 51 | 5 | HMOX1, S100G, SLC30A1, |
| Jejunum/ZnO | 23 days | PAK pathway | 12.7 | 620 | 9 | CDH2, PLA2G7, |
| IPEC-J2/ZnO | 2 h | PAK pathway | 15.0 | 731 | 18 | BMP2, CSF2, CXCL2, |
| Jejunum/ZnO | 23 days | Influenza A | 10.9 | 317 | 6 |
|
| IPEC-J2/ZnO | 2 h | Influenza A | 16.3 | 317 | 12 | DNAJB1, |
| Jejunum/ZnO | 23 days | Cytoskeleton remodelling keratin filaments | 20.9 | 48 | 5 | KRT7, PLEC, TUBA1C, TUBA8, TUBA3C |
| Jejunum/ZnO | 23 days | Cytoskeletal signalling | 13.0 | 242 | 6 | ARHGAP35, KRT7, MARK1, PLEC, PAK1, DES |
| Jejunum/ZnO | 23 days | Cytoplasmic microtubules | 24.5 | 102 | 7 | DYNC2H1, MARK1, PLEC, TUBA1C, TUBA8, TUBA3C, DES |
| IPEC-J2/ZnO | 2 h | Cell adhesion_ECM remodelling | 9.3 | 61 | 4 | HBEGF, IL8, PLAU, SERPINE1 |
| Jejunum/ZnO | 23 days | Cell adhesion molecules (CAMs) | 9.7 | 145 | 4 | CD8A, CDH2, VTCN1, |
| Jejunum/ZnO | 23 days | Cell adhesion gap junctions | 10.9 | 49 | 3 | TUBA1C, TUBA8, TUBA3C |
| IPEC-J2/ZnO | 6 h | Adhesion | 11.0 | 80 | 10 | ADAM9, CLDN1, CTNNB1, CYR61, DOCK1, ITGA5, MPZL1, NEDD9, NOV, SERPINE1 |
| Overlap rye | ||||||
| IPEC-J2 10 vs. 5%/rye | 2 h | Cell cycle | 11.1 | 538 | 24 | ATM, CASC5, CDC27, CENPF, CEP152, CNTRL, KIF20A, LMNA, MAD1L1, NINL, NIPBL, PCM1, PDS5B, PSMB4, RPS27A, SGOL2, SMC2, SMC3, SMC4, STAG2, SYNE2, TOP2A, TPR, UBB |
| Jejunum 10%/rye | 28 days | Cell cycle | 10.1 | 538 | 11 | ARPP19, OPTN, RAB1A, MAD2L1, FZR1, RFWD2, E2F4, NUP35, NUP214, YWHAG, RUVBL1 |
| IPEC-J2 10%/rye | 2 h | Cell cycle | 8.3 | 538 | 4 | ATM, CENPF, NIPBL, SYNE2 |
| Jejunum 5%/rye | 21 days | Cell cycle | 15.2 | 538 | 17 | ARPP19, CDK2, OPTN, RAB1A, CSNK2B, MAD2L1, CNTRL, PSMD11, CENPE, GINS2, E2F2, MCM10, SGOL1, NUP160, NUP214, SMC1B, RUVBL1 |
| Jejunum 10%/rye | 28 days | Cell cycle/checkpoint control | 7.9 | 229 | 6 | ARPP19, MAD2L1, VCP, YWHAG, MKI67, ZBTB17 |
| Jejunum 10 vs. 5%/rye | 28 days | Cell cycle/checkpoint control | 8.7 | 229 | 6 | ARPP19, MAD2L1, VCP, MKI67, MLH1, ZBTB17 |
| IPEC-J2 10 vs. 5%/rye | 2 h | Cell cycle/checkpoint control | 13.1 | 229 | 15 | ATM, CDC27, CEND1, FOSB, LMNA, NHEJ1, PCM1, RAD50, RAN, SMC2, SMC3, SMC4, SMG1, STAG2, TPT1 |
| IPEC-J2 10 vs. 5%/rye | 2 h | Biosynthesis of the | 46.3 | 696 | 51 | ACTB, EEF1A1, EEF1A2, EEF1G, FAU, GFPT1, LMAN1, LMNA, MBOAT4, |
| Jejunum 10 vs. 5%/rye | 28 days | Biosynthesis of the | 6.9 | 696 | 10 | ALG14, COQ2, RPL37, SRP9, ST3GAL4, LDHD, IGFBP1, PIGA, F2, ZBTB17 |
| Jejunum 5%/rye | 21 days | Biosynthesis of the | 15.6 | 696 | 20 | ARFGAP1, CTSG, GCNT3, EIF4B, ALG14, COQ2, RPL37, |
| IPEC-J2 5%/rye | 2 h | Biosynthesis of the | 87.5 | 696 | 39 | ACTB, EEF1A1, EEF1G, |
| Rye; related in vivo pathways | ||||||
| Jejunum 10 vs. 5%/rye | 28 days | Signalling by BMP | 6.8 | 48 | 3 | NUP214, TOB1, |
| Jejunum 10 vs. 5%/rye | 21 days | Ovarian infertility genes | 21.0 | 32 | 4 | ESR2, INHA, NR5A1, ZP3 |
| Jejunum 10 vs. 5%/rye | 21 days | Ca-dependent events | 9.6 | 247 | 4 | CYP11A1, NR5A1, OPRM1, STAR |
| Overlap amoxicillin | ||||||
| Jejunum/amox | 14 days | CC_FAT/GO:0015630 ~ microtubule cytoskeleton | 0.016 | 31c | 5 | IFT20, |
| IPEC-J2/amox | 6 h | CC_FAT/GO:0015630 ~ microtubule cytoskeleton | 0.241 | 707c | 21 | APC2, NIN, IFT80, FLOT1, ALMS1, |
| Jejunum/amox | 14 days | CC_FAT/GO:0005856 ~ cytoskeleton | 0.009 | 31c | 8 | ARPC1A, IFT20, MYL12A, |
| Amoxicillin; related in vivo pathways | ||||||
| Jejunum/amox | 14 days | Aurora B signalling | 10.2 | 39 | 2 | TACC1, STMN1 |
| Jejunum/amox | 6 h | Validated targets of C-MYC transcriptional repression | 17.9 | 62 | 11 | CCND1, CDKN1B, CEBPD, CLU, DDIT3, DKK1, NDRG1, NDRG2, RBL1, S100A7, |
| Jejunum/amox | 6 h | Cell cycle/checkpoint control | 11.9 | 229 | 18 | BRD2, CCND1, CDC25A, CDKN1B, CSNK1A1, DDIT4, FOSB, KAT5, NBN, NEK7, PLK3, RBBP8, RCC2, SMG1, TFAP2C, TP53BP1, YWHAG, |
aGeneAnalytics pathways with a high score (>18; corresponding with an FDR-corrected p value ≤0.0001) and medium score (>6.5; corresponding with an FDR-corrected p value ≤0.1) were retrieved. Enriched GO-terms with a p value of <0.05 were retrieved from DAVID, except for IPEC-J2 cells at 6 h. GO-terms with a p value of <0.25 were retrieved. Pathway annotations are from GeneAnalytics (http://geneanalytics.genecards.org).
bNumber of genes; total number of genes in a pathway or number of DEGs loaded in DAVID (for GO-term analysis)
cNumber of DEGs loaded in DAVID (for GO-term analysis)
dNumber of DEGs mapped to a pathway or to a GO-term
eOverlapping genes are italicized. Pathway annotations are from GeneAnalytics (http://geneanalytics.genecards.org).
Fig. 1KEGG mineral absorption pathway. Genes specifically responding to zinc in the jejunum or ileum of piglets are encircled in red and in IPEC-J2 cells in black. MT1A gene expression was upregulated in the ileum and jejunum of piglets, in IPEC-J2 cells at 2 h, and downregulated in IPEC-J2 cells at 6 h. Arrows indicate up (↑)- or down (↓)-regulation. Official gene symbols are provided for non-HUGO symbols used in the boxes of the pathway (FPN1 = SLC40A1, ZnT1 = SLC30A1, Zip1 = SLC39A4, CaBP9K = S100G)
Fig. 2KEGG TGF-beta signalling pathway. Genes specifically responding to rye in the jejunum of broilers are encircled in red and in IPEC-J2 cells in black. Overlapping genes ZFYVE16 and NOG are encircled by dashed red-black lines. The DEG ZBTB17 (alias MIZ1) and gene CDKNA1 (alias p21) were also part of the KEGG cell cycle pathway and integrated in the original scheme of the KEGG TGF-beta signalling pathway (encircled with a dashed line) and are discussed in the section of amoxicillin. Arrows indicate up (↑)- or down (↓)-regulation. Official gene symbols are provided for non-HUGO symbols used in the boxes of the pathway scheme (NOG = Noggin, SARA = ZFYVE16)